E2F4 and ribonucleotide reductase mediate S‐phase arrest in colon cancer cells treated with chlorophyllin
Open Access
- 11 May 2009
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 125 (9) , 2086-2094
Abstract
Chlorophyllin (CHL) is a water‐soluble derivative of chlorophyll that exhibits cancer chemopreventive properties, but which also has been studied for its possible cancer therapeutic effects. We report here that human colon cancer cells treated with CHL accumulate in S‐phase of the cell cycle, and this is associated with reduced expression levels of p53, p21, and other G1/S checkpoint controls. At the same time, E2F1 and E2F4 transcription factors become elevated and exhibit increased DNA binding activity. In CHL‐treated colon cancer cells, bromodeoxyuridine pulse‐chase experiments provided evidence for the inhibition of DNA synthesis. Ribonucleotide reductase (RR), a pivotal enzyme for DNA synthesis and repair, was reduced at the mRNA and protein level after CHL treatment, and the enzymatic activity was inhibited in a concentration‐dependent manner both in vitro and in vivo. Immunoblotting revealed that expression levels of RR subunits R1, R2, and p53R2 were reduced by CHL treatment in HCT116 (p53+/+) and HCT116 (p53−/−) cells, supporting a p53‐independent mechanism. Prior studies have shown that reduced levels of RR small subunits can increase the sensitivity of colon cancer cells to clinically used DNA‐damaging agents and RR inhibitors. We conclude that by inhibiting R1, R2, and p53R2, CHL has the potential to be effective in the clinical setting, when used alone or in combination with currently available cancer therapeutic agents. © 2009 UICCKeywords
Funding Information
- NIH (CA090890, CA65525, CA122959)
- NIEHS Center (P30 ES00210)
This publication has 69 references indexed in Scilit:
- Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancerGenome Biology, 2007
- Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNAProceedings of the National Academy of Sciences, 2007
- Bcl-2 overexpression in PhIP-induced colon tumors: cloning of the rat Bcl-2 promoter and characterization of a pathway involving β-catenin, c-Myc and E2F1Oncogene, 2007
- Structural mechanism of allosteric substrate specificity regulation in a ribonucleotide reductaseNature Structural & Molecular Biology, 2004
- Role of Mitochondria and Caspases in Vitamin D-mediated Apoptosis of MCF-7 Breast Cancer CellsJournal of Biological Chemistry, 2001
- Ribonucleotide Reductase, a Possible Agent in Deoxyribonucleotide Pool Asymmetries Induced by HypoxiaJournal of Biological Chemistry, 2000
- Controlled Protein Degradation Regulates Ribonucleotide Reductase Activity in Proliferating Mammalian Cells during the Normal Cell Cycle and in Response to DNA Damage and Replication BlocksJournal of Biological Chemistry, 2000
- CYCLINS AND CELL CYCLE CHECKPOINTSAnnual Review of Pharmacology and Toxicology, 1999
- Mechanisms of the in vitro antimutagenic action of chlorophyllin against benzo[a]pyrene: Studies of enzyme inhibition, molecular complex formation and degradation of the ultimate carcinogenMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1994
- Chemopreventive properties of chlorophyllin: inhibition of aflatoxin B1 (AFB1)-DNA binding in vivo and anti-mutagenic activity against AFB1 and two heterocyclic amines in the salmonella mutagenicity assayCarcinogenesis, 1991